Trial intelligence / Profile preview

Perioperative DOS plus tislelizumab for locally advanced gastric cancer

jRCTs051260209Phase 2

Key facts

Status
Recruiting
Start
Nov 2026
Countries
1
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Conditions
gastric adenocarcinoma
01

Overview

Phase 2, open-label, single-arm trial of tislelizumab, docetaxel, oxaliplatin and tegafur in gastric adenocarcinoma, sponsored by BeOne Medicines. Primary endpoint: Completion rate of preoperative DOS-Tisle therapy. Started Nov 2026; status: recruiting.

02

Design

1 arm
Study design
Non-randomizedOpen-labelSingle group
  • Perioperative DOS-Tisle

    Three cycles of preoperative tislelizumab plus docetaxel, oxaliplatin, and S-1 followed by curative gastrectomy and postoperative DOS-Tisle therapy.

03

Who it enrols

Adults with histologically confirmed gastric adenocarcinoma that is clinically T3-4 and/or node-positive, without distant metastasis except allowed para-aortic nodal metastasis at station 16a2/b1, and considered resectable with planned R0 surgery. Patients must have good performance status, adequate organ function, adequate oral or enteral nutrition, and no major autoimmune, interstitial lung, transplant, active infection, severe cardiac, pregnancy, or hepatitis B surface antigen positivity exclusions.

04

Endpoints

Primary

  • Completion rate of preoperative DOS-Tisle therapy

Secondary

  • Objective response rate

  • Pathological response rate

  • Pathological complete response rate

  • R0 resection rate

  • Postoperative DOS-Tisle therapy initiation rate

  • Postoperative DOS-Tisle therapy completion rate

  • Overall completion rate of perioperative DOS-Tisle therapy

  • Incidence of adverse events, including immune-related adverse events

Beyond the preview

Go deeper on jRCTs051260209.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCTs051260209.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call